Alzheimer's Disease is the most common neurodegenerative disorder. A hallmark of this disease is aggregation of the protein Tau into fibrillar tangles, which is ultimately linked to neuronal death 1, 2 . Oligomeric precursors of Tau fibrils are suspected to be the neurotoxic agent while fibrils themselves may be less harmful end products of the aggregation process 3, 4 . Evolutionary conserved families of molecular chaperones maintain protein homeostasis in healthy cells, preventing aggregation 5, 6 . Here, we investigate whether such chaperones could possibly reverse the aggregation reaction and dissolve Tau fibrils. Indeed we find that the human Hsp70 chaperone system disaggregates Tau fibrils. Both the bacterial and human Hsp70 chaperone systems disassemble fibril superstructures assembled of several fibril strands into single fibrils, indicating that this is an evolutionary conserved capacity of the Hsp70 system. However, further disaggregation of Tau fibrils into oligomers and even monomers is reserved to the human homologue. Thus, although bacteria possess an effective machinery to dissolve amorphous aggregates 7-9 , we see that they do not have the means to disaggregate fibrils. Fibrillar aggregates, therefore, require different chaperone systems than amorphous aggregates, and this is a property acquired by Hsp70 during evolution. This makes the Hsp70 system an interesting target for novel drug strategies in Alzheimer.
INTRODUCTION
Tau is an intrinsically disordered protein of 441 residues in its longest isoform 3, 10 . Its function is the stabilisation of microtubules, mediated by its repeat domain (Tau-Q244-E372; Tau-RD 11 ). Tau interaction with microtubules is controlled by phosphorylation, and in healthy neurons Tau is continuously degraded 12 . Formation of Tau fibrils is regarded as an irreversible process linked to the neuronal death in Alzheimer's disease, in which oligomeric intermediates are suspected as actual toxic species [2] [3] [4] . The neurotoxic effect of Tau aggregation is not depending on a specific form of aggregates. Tau fibrils in Alzheimer form dimeric straight filaments and paired filaments 13 . Tau fibrils in Pick's disease contain only three of the four repeats of the repeat domain and form monomeric fibrils with entirely different side chain pairing than the Alzheimer fibrils 14 . Tau-RD with the proaggregating mutation ΔK280 but lacking the five residues of the Alzheimer fibril aggregates even faster than the full-length protein and constitutes an established disease model, causing neuronal death and memory loss in mice 15 .
It is crucial for longevity of neurons to prevent any form of Tau aggregation. The molecular chaperones Hsp70 and Hsp90 are involved in controlling degradation of Tau, preventing uncontrolled appearance of free Tau [16] [17] [18] [19] . This process is disturbed when Tau fibrils form in Alzheimer's Disease. The role of chaperone control in the later steps of Tau aggregation, however, is poorly understood.
We wondered whether molecular chaperones could be capable to reverse aggregation of Tau. Recently it became clear that metazoan Hsp70 chaperone system has disaggregase activity 20 . Hsp70 chaperones are ATPdependent machines that are regulated by ATPase-stimulating J-proteins and nucleotide exchange factors. A trio consisting of the Hsp70 homologue Hsc70, the J-protein Hdj1 and the nucleotide exchange factor Apg2 disaggregates α-synuclein fibrils to monomers 21 . Hsc70 is the housekeeping Hsp70 chaperone and under normal conditions the most important cytosolic Hsp70 protein. Therefore, we set out to test whether the human Hsc70 system can disaggregate Tau fibrils.
RESULTS
For investigating disaggregation of Tau fibrils, we used the pro-aggregating ΔK280 variant of Tau-RD, with a FLAG tag to facilitate detection (Tau-RD*), which fibrillates more aggressively than the wildtype. It contains both Hsp70 binding sites and the largest part of the Tau fibril structure 13, 22, 23 . The lack of the highly charged and less hydrophobic Nterminus facilitates aggregation. We used the established heparin protocol to initiate fibril formation 24 . We confirmed by transmission electron microscopy (TEM) that Tau-RD* indeed forms fibrils with regular periodicity of 50-100 nm ( Fig. 1a and Fig. S1b) . Thus, we produced fibrils of this neurotoxic fragment to analyse disaggregation by chaperones.
To monitor aggregation, we separated monomers, oligomers and fibrils mixtures of Tau-RD* on density gradients followed by dot blotting detection with a fluorescently labelled antibody. Non-aggregated Tau-RD* sediments as monomers on top of the gradient (Fig. 1b , tube I, fraction 1). After induction of aggregation by heparin, the sample does not contain monomers anymore. Instead we observe a mixture of soluble oligomers in the middle of the gradient (Fig. 1b, tube II, fractions 6-11) while fibrils move to the bottom (tube I, fraction 12).
We now tested the potential of the human Hsc70 machinery to disaggregate Tau fibrils. We used heparin-aggregated Tau-RD* and added the chaperone system after fibril Density gradients of preformed, heparininduced Tau-RD* fibrillar superstructures, untreated (Unt.) or treated for 24 h (human system) or 2 h (bacterial system) with chaperones as indicated. Centrifugation was performed at 185,000 g for 1 h. c. Intensity profiling of (b), normalized to a 0 to 1 scale.
formation. Strikingly, the density gradient analysis revealed that Hsc70 generated monomers (Fig 1b, tube III) . The Hsc70 disaggregation activity was strictly ATPdependent (Fig 1b, tubes III and IV), indicating that disassembly of Tau fibrils works along the same mechanistic lines as other activities of Hsc70 in folding, unfolding and disassembly. The intensity profile of the dot blots visualised relative changes in the size distribution of Tau-RD* (Fig. 1c) . In the presence of the Hsc70 and ATP, the most prominent appearance of Tau-RD* is in fractions 1 and 2 (Fig. 1c, profile III) , corresponding to monomers and small oligomers. After Hsc70 action we did not observe defined particles anymore by TEM and residual protein material became positively stained (Fig. S1a) . Thus, fibrils and larger oligomers are not inert in the presence of a functioning Hsc70 system.
In disease, Tau is part of larger tangles. We wondered whether association of Tau into such larger superstructures might affect the ability of Hsc70 to disassemble fibrils. To this end we generated superstructures by growing fibrils at higher ionic strength. TEM images confirmed that under these conditions Tau fibrils form larger bundles (Fig. 2a and Fig. S2 ). We monitored Hsc70-dependent disassembly of these superstructures by density gradient (Fig.  2b and c) . Compared to the previous experiments on single fibrils we used smaller g-force and centrifuged the gradients for shorter time to optimise resolution for oligomers. Interestingly, the human Hsc70 system also disassembled the Tau superstructures into a mixture of monomers and oligomers in an ATP-dependent manner (Fig. 2b , tubes II and III). Again, after Hsc70 action we did not observe defined particles anymore by TEM and residual protein material became positively stained (Fig. S2) . Thus, human Hsc70 can disassemble Tau fibrils, independent of their superstructure. The Hsp70 system is conserved in evolution. The bacterial DnaK, together with its cochaperones, the J-protein DnaJ and the nucleotide exchange factor GrpE, can disaggregate small soluble aggregates. In cooperation with the Hsp100 disaggregase ClpB, lacking in the metazoan cytosol, DnaK also disaggregates large, amorphous aggregates 8, 25 . Notably, Hsp100 disaggregases are lacking in the metazoan cytosol. However, DnaK and ClpB alone do not disaggregate Tau-RD fibrils 9 . We confirmed that the bacterial system did not have any impact on single Tau fibrils (Fig.  1b , tubes V and VI; Fig. 1c; Fig. S1a ). Remarkably, however, when applying the bacterial Hsp70 system to fibril superstructures we noted that the superstructures were dissolved (Fig. 2b , tubes IV and VI; Fig. S2 ). Thus, the E. coli Hsp70 system can disassemble the fibril superstructures, but it cannot disassemble the fibrils themselves. We conclude that nicking of Tau fibrils is an activity only acquired for Hsp70 systems later in evolution. Notably, Hsp100 did not even contribute further to disaggregation of fibril superstructures (Fig. 2b , tubes IV and V; Fig.  2c ). We conclude that the bacterial Hsp70 and Hsp100 disaggregases lack the ability to disassemble single fibrils, despite their ability to effectively dissolve amorphous aggregates.
DISCUSSION
Our findings suggest that the disaggregation activity of Hsp70 consists of two capacitiesone linked to controlling fibril superstructure, which is an evolutionary conserved Hsp70 activity, the other linked to disaggregation of the fibril itself, which is reserved to the human homolog (Fig. 3) . Thus, the capacity to disaggregate Tau fibrils is a unique property of the human system. The bacterial Hsp70/Hsp100 systems are unable to dissolve fibrils, although they are highly active on amorphous aggregates. In yeast, the Hsp100 but not the Hsp70 shows disaggregating activity for fibrils, which may be correlated with the presence of prions in yeast 9, 26, 27 . This suggests that defibrillation is a meaningful Hsp70 activity acquired in evolution together with the increasing appearance of pro-fibrillic proteins.
Interestingly, metazoa lack cytoplasmatic Hsp100 disaggregases. Thus, the ability to disaggregate amyloid structures by the Hsp70 machinery may have co-evolved in metazoa at the expense of the Hsp100 disaggregases.
The ability of the Hsp70 system to dissolve neurotoxic fibrils of both Tau and α-synuclein endows human neurons with chaperone machinery capable of processing various amyloids. This is potentially relevant for other fibril diseases such as ALS or corea Huntington. It may be this fibril dissolving power that can also control liquid-liquid phase separation. Inhibiting Hsp70 increases the halflife of stress granules, pointing indirectly a role of this chaperone in the disassembly of stress granules 28 .
Hsp70 is a central node of the proteostasis network, which gradually collapses during aging 29, 30 . While it is established that the chaperone network controls protein homeostasis of monomeric Tau, our data show that Hsc70 has the ability to approach Tau after initiation of aggregation [16] [17] [18] [19] . This activity may be a double-edged sword. It may contribute to successful prevention of fibril formation for the first decades of our life, but it remains to be seen whether Hsc70 could contribute to generate potentially toxic oligomers from apparently inert fibrils. A natural disaggregase in neurons may be an interesting target for novel drug strategies in Alzheimer. Thus, It is an exciting challenge to control function of the Hsp70 machinery in the later stages of life.
METHODS

Protein purification
Purification of Tau-RD* We overproduced N-terminally FLAG-tagged (DYKDDDDK) Human Tau-RD (Q244-E372, also referred to as K18, with pro-aggregation mutation ΔK280) recombinantly in E. coli BL21 Rosetta 2 (Novagen), with additional removable N-terminal His 6 -Smt-tag (MGHHHHHHGSDSEVNQEAKPEVKPEVK PETHINLKVSDGSSEIFFKIKKTTPLRRLM EAFAKRQGKEMDSLRFLYDGIRIQADQTP EDLDMEDNDIIEAHREQIGG). Cells were harvested, flash-frozen in liquid nitrogen and stored at -80°C until further usage. Pellets were thawed in a water bath at 37°C and resuspended in 50 mM HEPES-KOH pH 8.5 (Sigma-Aldrich), 50 mM KCl (SigmaAldrich), ½ tablet/50 ml EDTA-free protease inhibitor (Roche), 5 mM β-mercaptoethanol (Sigma-Aldrich). Cells were disrupted by an EmulsiFlex-C5 cell disruptor (Avestin). Lysate was cleared by centrifugation, filtered with a 0.22 µm polypropylene filter (VWR) and supernatant was purified using an ÄKTA Purifier chromatography system (GE Healthcare). First, protein was loaded onto a POROS 20MC (Thermo Fischer Scientific) affinity purification column in 50 mM HEPES-KOH pH 8.5, 50 mM KCl, eluted with a 0-100% linear gradient (5 Column Volumes, CV) of 1 M imidazole. Fractions of interest were collected and concentrated in a buffer concentrator (Vivaspin, cut-off 10 kDa) to final volume of 3 ml. The concentrated sample was desalted with a PD-10 desalting column (GH Healthcare) in 50 mM HEPES-KOH pH 8.5, ½ tablet/50 ml Complete protease inhibitor (Roche)) and 5 mM β-mercaptoethanol. The His 6 -Smt tag was removed by Ulp1 treatment, shaking at 4°C over night. Next day, protein was loaded onto a POROS 20HS (Thermo Fischer Scientific) cation exchange column equilibrated with 50 mM HEPES-KOH pH 8.5. Protein was eluted with a 0-100% linear gradient (15 CV) of 2 M KCl (Carl Roth). Fractions of interest were collected and loaded onto a HiLoad 26/60 Superdex 200 pg (GE Healthcare Life Sciences) size exclusion column equilibrated with 25 mM HEPES-KOH pH 7.5, 75 mM KCl, 75 mM NaCl and 10 mM DTT. Fractions of interest were further concentrated to the desired final concentration using a concentrator (Vivaspin, cut-off 5 kDa). Protein concentration was measured using an ND-1000 UV/Vis spectrophotometer (Nanodrop Technologies) and purity was assessed with SDS-PAGE. Protein was aliquoted and stored at -80°C.
Protein purification of DnaK E. coli DnaK was purified by adapting a published procedure 31, 32 . We overproduced Nterminally His 6 -Smt3-tagged bacterial DnaK recombinantly in ΔdnaK52 cells (BB1994). Cell pellets were resuspended in lysis buffer (20 mM Tris-HCl pH 7.9, 100 mM KCl, 1 mM PMSF) and disrupted by an EmulsiFlex-C5 cell disruptor. Lysate was cleared by centrifugation, filtered with a 0.22 µm polypropylene filter and loaded onto a column with Ni-IDA resin (Macherey-Nagel). Column was washed with 20 CV of lysis buffer, 10 CV of ATP buffer (20 mM Tris-HCl pH 7.9, 100 mM KCl, 5mM MgCl2, 5 mM ATP), and 2 CV of lysis buffer. Protein was eluted with 20 mM Tris-HCl pH 7.9, 100 mM KCl, 250 mM imidazole. The His 6 -Smt3 tag was removed by Ulp1 treatment. After cleavage and dialysis against lysis buffer, the protein mixture was loaded onto a Ni-IDA column and the flowthrough fraction containing tag-free DnaK was collected. DnaK was loaded onto a Resource Q (GE Healthcare) anion exchange column equilibrated with 40 mM HEPES-KOH pH 7.6, 100 mM KCl, 5 mM MgCl2. DnaK was eluted with a 0.1-1 M linear gradient (10 CV) of KCl. The protein concentration was measured using an ND-1000 UV/Vis spectrophotometer and purity was assessed with SDS-PAGE. Protein was aliquoted and stored at -80°C.
Protein purification of DnaJ E. coli DnaJ was purified by adapting a published procedure 32, 33 . We overproduced DnaJ in E. coli strain W3110. Cell pellets were resuspended in lysis buffer (50 mM Tris-HCl pH 8, 10 mM DTT, 0.6% (w/v) Brij 58, 1 mM PMSF, 0.8 g/l Lysozyme) and disrupted by an EmulsiFlex-C5 cell disruptor. Lysate was cleared by centrifugation and filtered with a 0.22 µm polypropylene filter. One volume of buffer A (50 mM Sodium Phosphate pH 7, 5 mM DTT, 1 mM EDTA, 0.1% (w/v) Brij 58) was added to the supernatant and protein was precipitated by addition of (NH4) 2 SO 4 to a final concentration of 65% (w/v). Protein was pelleted by centrifugation (15,000 g, 30 min), pellet was dissolved in 220 mL buffer B (50 mM Sodium Phosphate pH 7, 5 mM DTT, 1 mM EDTA, 0.1% (w/v) Brij 58, 2 M Urea) and dialysed against buffer B. DnaJ was then loaded onto a POROS 20HS cation exchange column equilibrated with buffer B, washed with buffer B and eluted with a 0-0.66 linear gradient (15 CV) of KCl. Fractions of interest were pooled and dialysed against buffer C (50 mM Tris-HCl pH 7.5, 2 M urea, 0.1% (w/v) Brij 58, 5 mM DTT, 50 mM KCl), then the sample was loaded onto a hydroxyapatite column equilibrated with buffer C. The column was first washed with 1 CV of buffer C supplemented with 1 M KCl, and then with 2 CV of buffer C. DnaJ was eluted with a 0%-50% linear gradient (1 CV) of buffer D (50 mM Tris-HCl pH 7.5, 2 M urea, 0.1% (w/v) Brij 58, 5 mM DTT, 50 mM KCl, 600 mM KH 2 PO 4 ) and 2 CV of 50% buffer D. Fractions of interest were pooled and dialysed against buffer E (50 mM Tris-HCl pH 7.7, 100 mM KCl). Protein concentration was measured using an ND-1000 UV/Vis spectrophotometer and purity was assessed with SDS-PAGE. Protein was aliquoted and stored at -80°C.
Protein purification of GrpE E. coli GrpE was purified by adapting a published procedure 32, 34 . We overproduced GrpE in ΔdnaK52 cells (BB1994). Cell pellets were resuspended in lysis buffer (50 mM TrisHCl pH 7.5, 100 mM KCl, 3 mM EDTA, 1 mM PMSF) and disrupted by an EmulsiFlex-C5 cell disruptor. Lysate was cleared by centrifugation and filtered with a 0.22 µm polypropylene filter. Protein was precipitated by addition of (NH4) 2 SO 4 to a final concentration of 0.35 g/ml. Protein was pelleted by centrifugation (15,000 g, 30 min), pellet was dissolved in 200 mL buffer A (50 mM Tris-HCl pH 7.5, 100 mM KCl, 1 mM DTT, 1 mM EDTA, 10% glycerol) and dialysed twice against the same buffer for 4 h. Protein was loaded onto a HiTrap Q XL anion exchange column equilibrated with buffer A and then eluted using a linear gradient of buffer B (50 mM Tris-HCl pH 7.5, 1 M KCl, 1 mM DTT, 1 mM EDTA, 10% glycerol). Fractions of interest were dialysed against buffer C (10 mM Potassium Phosphate pH 6.8, 1 mM DTT, 10% glycerol). GrpE was loaded onto a Superdex 200 pg size exclusion column equilibrated with buffer A and concentrated using a HiTrap Q XL anion exchange column with a steep gradient. Protein concentration was measured using an ND-1000 UV/Vis spectrophotometer and purity was assessed with SDS-PAGE. Protein was aliquoted and stored at -80°C.
Protein purification of Hsc70
Human Hsc70 (gene name: HSPA8) was purified by adapting a published procedure 35 . We overproduced N-terminally His 6 -Smt3-tagged Hsc70 recombinantly in E. coli BL21 Rosetta 2. Cell pellets were resuspended in lysis buffer (20 mM Tris-HCl pH 7.9, 100 mM KCl, ½ tablet/50 ml EDTA-free protease inhibitor) and disrupted by an EmulsiFlex-C5 cell disruptor. Lysate was cleared by centrifugation, filtered with a 0.22 µm polypropylene filter and supernatant was loaded onto a column with Ni-IDA resin. Column was washed with 20 CV of lysis buffer (Complete Protease Inhibitor instead of the EDTA-free one), 20 CV of high salt buffer (20 mM Tris-HCl pH 7.9, 1 M KCl) and again with 2 CV of lysis buffer. The column was then slowly washed with 10 CV of ATP-buffer (40 mM Tris-HCl pH 7.9, 100 mM KCl, 5 mM MgCl 2 , 5 mM ATP) to elute bound substrates. Protein was eluted with two times 1 CV of elution buffer (40 mM Tris-HCl pH 7.9, 100 mM KCl, 250 mM imidazole). Ulp1 was added to the elution and sample was dialyzed overnight against dialysis buffer (40 mM HEPES-KOH pH 7.6, 10 mM KCl, 5 mM MgCl 2 ). Protein was then loaded on Ni-IDA material, flow-through containing Hsc70 was collected and loaded onto a POROS 20HQ (Thermo Fischer Scientific) cation exchange column. Hsp70 was eluted with a linear gradient of elution buffer (40 mM HEPES-KOH pH 7.6, 1 M KCl, 5 mM MgCl2, 10 mM β-mercaptoethanol, 5% glycerol) and dialysed against 40 mM HEPES-KOH pH 7.6, 50 mM KCl, 5 mM MgCl 2 , 10 mM β-mercaptoethanol, 10% glycerol. Protein concentration was measured using an ND-1000 UV/Vis spectrophotometer and purity was assessed with SDS-PAGE. Protein was aliquoted and stored at -80°C.
Protein purification of Hdj1
Human Hdj1 (gene name: DNAJB1) was purified by adapting a published procedure 32, 36 . We overproduced N-terminally His 6 -Smt3-tagged human Hdj1 recombinantly in in E. coli BL21 Rosetta 2 strain. Cell pellets were resuspended in lysis buffer (20 mM Tris-HCl 20 pH 7.9, 100 mM KCl, ½ tablet/50 ml EDTA-free protease inhibitor) and disrupted by an EmulsiFlex-C5 cell disruptor. Lysate was cleared by centrifugation, filtered with a 0.22 µm polypropylene filter, loaded onto a POROS 20MC affinity purification column equilibrated with lysis buffer, then eluted with a 0-100% linear gradient (5 CV) of 1 M imidazole. The His 6 -Smt tag was removed by Ulp1 treatment. After cleavage and dialysis against 25 mM HEPES-KOH, 350 mM KCl, 5 mM MgCl 2 , 5 mM β-mercaptoethanol, the protein mixture was loaded onto a POROS 20HS cation exchange column equilibrated with 50 mM HEPES-KOH pH 8.5. Protein was eluted with a 0-100% linear gradient (15 CV) of 2 M KCl. Fractions of interest were buffer exchanged against 25 mM HEPES-KOH pH 7.5, 75 mM KCl, 75 mM NaCl and 10 mM DTT, then further concentrated using a concentrator. Protein concentration was measured using an ND-1000 UV/Vis spectrophotometer and purity was assessed with SDS-PAGE. Protein was aliquoted and stored at -80°C.
Protein purification of Apg2
Human Apg2 was purified by adapting a published procedure 32, 35 . We overproduced Nterminally His 6 -Smt3-tagged human Apg2 recombinantly in in E. coli BL21 Rosetta 2 strain. Cell pellets were resuspended in lysis buffer (40 mM Tris-HCl pH 7.9, 100 mM KCl, 5 mM ATP, ½ tablet/50 ml EDTA-free protease inhibitor) and disrupted by an EmulsiFlex-C5 cell disruptor. Lysate was cleared by centrifugation, filtered with a 0.22 µm polypropylene filter and loaded onto a column with Ni-IDA resin. Column was washed with 20 CV of wash buffer (40 mM Tris-HCl pH 7.9, 100 mM KCl, 5 mM ATP) followed by elution with elution buffer (40 mM Tris-HCl pH 7.9, 100 mM KCl, 300 mM imidazole). Protein was then loaded on a HiPrep 26/10 Desalting Column equilibrated with 20 mM Tris-HCl pH 7.9, 100 mM KCl, 10% glycerol. The His 6 -Smt tag was removed by Ulp1 shaking at 4°C over night, in the presence of 5 mM ATP. The day after, protein was loaded onto a HiLoad 16/600 Superdex 200pg size exclusion column equilibrated with 40 mM HEPES-KOH pH 7.6, 10 mM KCl, 5 mM MgCl2, 10% glycerol. Fractions of interest were loaded onto a Resource Q anion exchange column equilibrated with 40 mM HEPES-KOH pH 7.6, 10 mM KCl, 5 mM MgCl2, 10% glycerol. Protein was eluted with a 0-100% linear gradient (10 CV) of 1 M KCl. Protein concentration was measured using an ND-1000 UV/Vis spectrophotometer and purity was assessed with SDS-PAGE. Protein was aliquoted and stored at -80°C.
Protein purification of ClpB E. coli ClpB was purified by adapting a published procedure 8 . We overproduced C- Fractions of interest were further concentrated to the desired final concentration using a concentrator. Protein concentration was measured using an ND-1000 UV/Vis spectrophotometer and purity was assessed with SDS-PAGE. Protein was aliquoted and stored at -80°C.
Protein aggregates
Monomeric Tau-RD* (10 µM) was aggregated in 25 mM HEPES-KOH pH 7.5 with Complete protease inhibitor (1/2 tablet/50 ml), DTT 10 mM (Thermo-Scientific) and 2.5 µM of Heparin (Santa Cruz Biotech). Fibrils were aliquoted and flash frozen after 24 h of aggregation at 37°C, shaking. Single fibrils were obtained by in aggregation buffer containing 75 mM KCl / 75 mM NaCl, whereas fibrillar superstructures were obtained in aggregation buffer containing 500 mM KCl / 75 mM NaCl.
Disaggregation experiments
Chaperones mix (10 µM Hsc70, 5 µM Hdj1, 2,3 µM Apg2 for human system; 10 µM DnaK, 2 µM DnaJ and 5 µM GrpE for bacterial system) and Tau fibrils (Tau monomeric concentration: 2.5 µM) were incubated at 37°C, shaking at 180 rpm. Incubation time for each experiment is specified in the text. After incubation, samples were loaded completely on top of density gradients composed of a 10 to 40% sucrose gradient. Gradients were run on a Sorvall WX Ultra Series Centrifuge WX80 (Thermo Scientific), time and centrifugal forces depending on the experiment. Fractions were collected manually, each fraction 1/12 th of the total volume.
Transmission Electron Microscopy
Specimens were prepared for Transmission Electron Microscopy using a negative staining procedure. Briefly, a 5 µl drop of sample solution was adsorbed to a glow-discharged (twice for 20 s, on a Kensington carbon coater) pioloform-coated copper grid, washed five times on drops of deionised water, and stained with two drops of freshly prepared 2.0% Uranyl Acetate, for 1 and 5 minutes, respectively, and subsequently air dried. Samples were imaged at room temperature using a Tecnai T20 LaB 6 electron microscope operated at an acceleration voltage of 200 kV and equipped with a slow-scan Gatan 4K x 4K CCD camera. Images were acquired at a defocus value of 1.5 µm. Magnification values and pixel sizes on specimen level are summarised in Supplementary Table S1 .
Production of density gradients
Density gradients were formed by dissolving 10% and 40% sucrose (Sigma-Aldrich), in 25 mM HEPES pH 7.5, 75 mM KCl, 75 mM NaCl. Gradients were set up in polyallomer centrifuge tubes (Beckmann) by filling them to half volume with 40% sucrose and topping them up with an equal amount of 10% sucrose. Gradients were formed by tilting the tubes horizontally for 3 h at room temperate and then tilting them back to vertical position. Tubes were stored overnight at 4°C.
Dot blot analysis of density gradients
Dot blot was performed using a dot blot apparatus (BioRad) and nitrocellulose membrane 0.1 µM (Sigma-Aldrich) washed with PBS. Each well was filled with 150 µL of sample, incubated on the membrane 10 minutes at room temperature and then pulled through by applying vacuum. Nitrocellulose membranes were blocked with PBS blocking buffer (LI-COR) at room temperature for 1 hour and then incubated with primary antibody monoclonal anti-FLAG M2 (F3165, Sigma Aldrich, working dilution 1:1000) at room temperature for 1 hour. After three washes with PBS, secondary antibody Donkey anti Mouse IgG IR Dye 800 conjugated (610-732-002, Rockland, 1:5000) was added at room temperature for 45 minutes. After additional 2 washes with PBS-T and one final wash with PBS, detection was performed using Odyssey CLx (LI-COR). Quantification was performed via Image Studio Lite (LI-COR).
Dot blot profiling
For each tube, a rectangle encompassing all 12 fractions was drawn. The rectangle height corresponded to half diameter of each dots. Profiles were obtained via ImageJ software. Raw data was normalized to 0-1 range and plotted. The presence of visible aggregates in higher fractions precluded linear interpretation, as larger particles affect both accessibility for the antibody and the fluorescence signal itself.
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